Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08JMI
|
|||
| Former ID |
DCL001139
|
|||
| Drug Name |
ALN-VSP
|
|||
| Drug Type |
RNAi therapeutics
|
|||
| Indication | Liver cancer [ICD-11: 2C12; ICD-10: C22] | Phase 1 | [1] | |
| Company |
Alnylam Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Kinesin spindle messenger RNA (KIF11 mRNA) | Target Info | . | [1] |
| Reactome | MHC class II antigen presentation | |||
| Kinesins | ||||
| WikiPathways | MHC class II antigen presentation | |||
| Kinesins | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc (2011). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.